Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Merger Possibility?
HINTS! We are all aware of Dr. Missling's series of 1000 share buys prior to 2015 CTAD. Here is a listing of Anavex's SEC 8K filings that has served as more than just hints to me.
7/5/2013 - Dr. Missling's first contract for three years through
July 5,2016
7/5/16 - First amendment to his contract to extend employment for three years and also provided a large salary raise and many options to be vested over the three year period.
7/7/16 - Clarification of options plus an addition of the following
"UPON A CHANGE OF CONTROL ALL PREVIOUSLY GRANTED BUT UNVESTED OPTIONS SHALL VEST"
7/22/16 - Further clarifications of Missling's options.
Here is the listing of the quantity and dates of options granted to the granted to the BOD on FORM 4s filed with the SEC.
...............7/16/16..........9/22/16
Bernd.........50,000.........100,000
Favus..........1,500.........100,000
Skarpelos.... 50,000......100,000
Missling........................500,000 (In addition to contract options)
Boenisch......................106,696
Steffen.........................100,000
9/28/16 MTA to Biogen filed with the SEC.
????? QUIET PERIOD ?????
Also, Dr. Missling has stated many times that there is no need for funds.
I have a feeling that the BOD has all of the information they need and I'll rely on that.
Here is an Bloomberg article about Biogen.
Biogen’s CEO Is Out After Management Changes, Stalled Sales
by Doni Bloomfield
July 21, 2016 — 7:07 AM EDT July 21, 2016 — 11:48 AM EDT
George Scangos to leave in ‘coming months’; search beginning
Adjusted earnings beat estimates; share buyback announced
George Scangos. Photographer: David Paul Morris/Bloomberg
Biogen Inc. Chief Executive Officer George Scangos, who helped build the U.S. drugmaker into a powerful player in multiple sclerosis treatments, will leave the company after a series of top managers were replaced and sales of its biggest product stalled.
Scangos, 68, will stay on until a replacement is found, Biogen said in a statement Thursday in which it also reported second-quarter earnings. In the last year, the Cambridge, Massachusetts-based company announced new heads of sales and research, and its biggest product, the multiple sclerosis pill Tecfidera, disappointed investors.
His departure wasn’t a shock, given the company’s recent performance, Michael Yee, an analyst with RBC Capital Markets Corp., said by e-mail. “This is one where people thought there could be change given all that has gone on in the past year or so. The company’s next leader will face many of the same challenges that Scangos did in recent years -- how to advance the research and development pipeline of a storied biotechnology company that has made big, risky bets in diseases like Alzheimer’s, with mixed results. They’ll also need to boost sales of current products, which have surprised investors -- for good and bad -- in the competitive multiple sclerosis market.
Biogen will likely look outside the company for a new chief, according to Geoffrey Porges, an analyst at Leerink Partners.
Swooping In
“I imagine what they’re looking for is someone who’s already running a smaller company or has a track record of leading an integrated business unit focused on the neurosciences,” he said. Biogen has said it plans to concentrate on neurological drugs, and is working to spin off its treatments for the blood-clotting disorder hemophilia as a separate public company.
(My emphasis here.)
As a refresher, here is a portion of a post I made previously that defines Quiet Period. Xena added additional info about it also.
Guidelines[edit]
During a Quiet Period, a publicly listed company cannot make any announcements about anything that could cause a normal investor to change their position on the company's stock. Normally, that means the company does not discuss any of the following:
New deals or wins signed in that current quarter. Announcements about previously sold implementations going live are allowed but must be explicitly described as such.
Management changes
Progress against company goals
Major product or service announcements
Major partnership announcements
My emphasis.
HINTS! We are all aware of Dr. Missling's series of 1000 share buys prior to 2015 CTAD. Here is a listing of Anavex's SEC 8K filings that has served as more than just hints to me.
7/5/2013 - Dr. Missling's first contact for three years
7/5/16 - First amendment to his contract to extend employment for three
years. This provided a large salary raise and many options to be
vested over the three year period.
7/7/16 - Clarification of options plus an addition of the following
"UPON A CHANGE OF CONTROL ALL PREVIOUSLY GRANTED BUT UNVESTED
OPTIONS SHALL VEST"
7/22/16 - Further clarifications of options.
Here is the listing of the quantity and dates of options granted to the granted to the BOD on FORM 4s
-------------- 7/16/16 -------- 9/22/16
Bernd --------50,000---------100,000
Favus -------- 1,500-------- 100,000
Skarpelos --- 50,000---------100,000
Missling---------------------500,000 (In addition to contract options)
Boenisch---------------------106,696
Steffen----------------------100,000
9/28/16 MTA to Biogen filed with the SEC.
????? QUIET PERIOD ?????
I have a feeling that the BOD has all of the information they need and I'll rely on that.
Jimmy - I never ever saw anything that indicated that Anavex's presentation was originally schedule for Friday.
As I recall the poster almost sounded to me that he had inside CTAD info regarding the scheduling but on the other hand it might just have been a misunderstanding.
George - I have felt that Anavex's oral presentation immediately before the final keynote address was an intentional placement so Lilly's placement would make it an alpha~omega situation.
___________________________________________________________________________
8.45 a.m OC60 - 9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study
in Mild-to-Moderate Alzheimer’s Disease Patients
Stephen Macfarlane, MD1
, Marco Cecchi, PhD2
, Paul Maruff, PhD3
, Kristina M Kapiak4
, Christopher U Missling, PhD4
(1) Caulfield Hospital, Melbourne, Australia, (2) Neuronetrix, Louisville, KY, USA, (3) Cogstate Ltd., Melbourne, Australia, (4) Anavex Life Sciences Corp., New York, NY,
USA
9.00 a.m KEYNOTE 5
Alzheimer’s disease: from Proteinopathy to Prevention
Introduction: Zaven Khachaturian
Randall Bateman, Washington University School of Medicine, St.Louis, MO, USA_______________________________________________________________________
"Biogen needs AVXL more than AVXL needs Biogen"
I forgot which poster stated this but here is a portion of an article written by Todd Campbell in The Motley Fool.
Despite outperforming expectations, year-over-year top-line growth remained tepid compared to the company's historical rates, and a decision by management to shelve development of a next-generation multiple sclerosis (MS) therapy marked a second failure of a key pipeline candidate this year.
In June, the company reported disappointing mid-stage results for anti-lingo, a therapy it hoped could restore the damage to a nerve's myelin sheath that causes MS symptoms. Then in its conference call with investors in October, Biogen announced it's abandoning MT-1303, a S1P modulator that Biogen once hoped could insulate itself against fast-approaching competition from Celgene and Novartis , two companies developing their own S1P drugs. After reviewing MT-1303's market potential, Biogen is walking away from MT-1303 only a year after securing the rights to it from Mitsubishi Tanabe .
Michael D. Ehlers, executive VP of research and development, said, "As we looked at how the landscape was evolving, both in terms of the regulatory competitive landscape, changing features there, and the corresponding fit with our strategic priorities about where we could best allocate resources based on our own expertise and competency -- we just determined that it wasn't as good of a fit as other things which we could allocate our resources toward."
Now what
Biogen is the dominant player in MS treatment, and that's not going to change overnight. However, new drugs are on the horizon that could eat away at Biogen's market share over the next few years, so investors are right to be concerned about Biogen's R&D stumbles.
Management isn't giving up on MS, but it is shifting a lot of R&D focus to other indications, including Alzheimer's disease. If that R&D pays off, then management could tap into a massive and underserved market. However, this research is still ongoing, and it could be a while before we learn how effective these "moonshots" are at curbing disease.
________________________________________________________________________
Why Biogen Inc. Stock Lost 10.5% of Its Value In October
November 09, 2016, 08:03:00 AM EDT By Todd Campbell, Motley Fool
________________________________________________________________________
McMagyar I agree with a bear trap.
I posted this early somewhat in jest but with a deep down wish that it could be true.
drv17 Member Level Friday, 10/28/16 10:58:43 AM
Re: None
Post #
78834
of 81284 Go
How about some conspiracy theory fun ?
1. Anavex reported great results at CTAD 2015
2. Stock was shorted, distorted, manipulated and law suits filed.
3. Congress requested to meet with Dr. Missling and he explained the problems Anavex is having to save the government money and to save
"Obama Care".
4.SEC meets with Anavex at the request of Congress.
5. Plan is developed to monitor and record all transactions, posts, articles and lawsuits filed on Anavex around the AAIC-2016 Conference in July and CTAD-2016 Conference in December as well as any other positive news release.
6. Then after the holidays SEC goes to work to be sure the "Most Hated Man in America" previously at Turing Pharmaceuticals will have the company of many of his associates in the future and for a long time!!
Thank you. I had thought it had been listed and was curious why it isn't now especially after just being presented at the Neuro conference Nov. 14th.
Anavex 1066 was not listed in pipeline when I checked this morning.
Does anyone know the reason for this?
I have an inquiry in with IR but I don't expect a reply very soon.
Right to Try
McMagyar, Jimmy6969 and any other similarly affected.
Here is a portion of an article about our new Vice President Mike Pence regarding his position on the matter. Also we heard President Elect Trump's position regarding the FDA.
_________________________________________________________________________
RIGHT TO TRY POSTED ON MARCH 24, 2015 | PRESS RELEASE
INDIANA GOVERNOR MIKE PENCE SIGNS RIGHT TO TRY LEGISLATION INTO LAW
Governor becomes fourth this year to help terminally ill access investigational medications.
Indianapolis—Today Governor Mike Pence signed into law a bill to give terminally ill patients access to medicines that have passed Phase 1 of the FDA approval process but are not yet on pharmacy shelves. The bill passed both the state House and Senate with unanimous, bipartisan votes. HB 1065—The Indiana Right to Try Act—was sponsored by Sen. Ed Charbonneau (R) and state Rep. Charlie Brown (D).
“We all know the pain of losing someone we love to a terminal illness,” said Darcy Olsen, the president of the Goldwater Institute, the group leading the national, bipartisan Right To Try effort. “If you know there’s a treatment that is helping people survive, who is anyone to say ‘No; you don’t have the right to try to save your own life or to save your child’s life’? Of course you do. Of course people should have the right to try promising medicines when they are fighting for their lives.”
Right To Try laws are already in place in Arizona, Arkansas, Colorado, Louisiana, Michigan, Missouri, South Dakota, and Wyoming. Twenty-five additional states are considering the law this year. Lawmakers in Mississippi, Montana, Virginia and Utah have sent similar bills to their governors for approval.
________________________________________________________________________
It would be very effective, imo if some of you with the knowledge and skills collaborated to compose a sample email for all of us to send to all of our senators and congressmen. If this could be a coordinated effort to reach virtually everyone of them within a short time frame, it is possible that we could bring some pressure to get A2-73 available to those in need. I realize that the 114th Congress is nearing completion but we could repeat the effort shortly after the 115th Congress convenes.
Here is a link to get the contact information for each of them as well as the contact information for each State Senator and representative.
________________________________________________________________________
Elected Officials | USAGov
www.usa.gov › Government Agencies and Elected Officials
_______________________________________________________________________-
I should have highlighted this.
All embargoed abstracts will be made available on December 8 at 8 a.m. PT at www.ctad-alzheimer.com.
CTAD embargo policy.
Home
ABOUT CTAD
PROGRAM
LOCATION
REGISTRATIONS
PRESS AND FAQS
SPONSORS
CTAD EMBARGO POLICIES AND FAQS
You are here
You Are Here: Home » CTAD Embargo Policies And FAQs
CTAD Embargo Policies and FAQs
The International Conference on Clinical Trials for Alzheimer’s Disease (CTAD) is an annual conference organized and planned by Alzheimer’s disease clinical researchers to share scientific information with each other. The 9th annual CTAD will be held December 8-10 in San Diego, CA - USA.
Credentialed members of the media are allowed to receive a free registration to the conference. To request your free pass to CTAD 2016 please contact Benedicte CLEMENT at ctad@ant-congres.com.
When are abstracts available?
All embargoed abstracts will be made available on December 8 at 8 a.m. PT at www.ctad-alzheimer.com. Our embargo policies are strictly enforced. All research is embargoed until the date/time that it is shared at a CTAD presentation, symposia or poster session. After the abstract presentation, you may publish/write on the abstract content.
Can I discuss CTAD abstract content before the embargo lifts?
Presentation or discussion of embargoed content at satellite meetings or press conferences before the CTAD embargo lifts is prohibited.
CTAD-Alzheimer | 8th Clinical Trials on Alzheimer’s Disease
www.ctad-alzheimer.com
Ziggy I believe McMagyar was trying to point out that the current negative sentiments will change to the negative argument of "that it is too expensive to buy" after the potential of the company is proven down the road.
Anavex 1066 I haven't seen any discussion about this today.
I thought a regular poster on this site might have mentioned it but I can't post to them to ask about it.
makemydaze Monday, 10/03/16 05:06:43 PM
Re: None
Post #
77125
of 80085 Go
Anavex is presenting a poster on Nov 13th at Neuroscience 2016 in San Diego. Poster is up from 8am to noon. They are presenting data on - - Anavex 1066 for Neuropathic and Visceral Pain. Credit to another poster for finding this -
http://www.abstractsonline.com/pp8/index.html#!/4071/presentation/13786
I tried to agree on another post but was blocked. Not sure why. (Apparently after I asked a question about Missling) Now I don't see their posts.
Anyway, One thing that stands out to me is that Dr. Missling was awarded 500,000 options (filed w/ SEC 7/26 ) and the the Biogen MTA was filed with SEC on 9/28. We haven't heard anything substantial from the company since.
Do you think it could be just a little misleading ?
McMagyar -I'm sorry you are limited to only one post. I appreciate your analytical approach to the information that we have available.
Little mentioned recently on this board is the actions of the BOD. They have access to all of the inside information including trials and outside negotiations and monetary requirements.
In July they renegotiated Dr. Missling's contract to give him a very nice raise as well as granting him many options.( This despite at the time that some others portended that the results were mediocre ?? )
Around the time of the Biogen announcement at the end of September, The BOD again awarded Dr. Missling another 500,000 options. The entire BOD was awarded 100,000 options at that time.
My take is that Board of Directors apparently has a very positive outlook. Also, I would think that Mr. Skarpelos would watch his investment very carefully in the company that he started.
Jonjones325
Perhaps I was too subtle in my post #79644.
Thank you for all of your cut and pastes. I am well aware of them.
I have a solid belief in Ananvex's science, management and SAB and have a very substantial investment in it for my estate.
I posed the possibility of a "quiet period" in post #78992 on 10/29/16 and firmly believe that is the case. I later responded to your concerns about transparency with my post #79252 copied here.
drv17 Member Level Monday, 10/31/16 10:23:35 AM
Re: Jonjones325 post# 79246
Post #
79252
of 79667 Go
Jon Jones I will re-post this as a possibility (and my hope).
Guidelines[edit]
During a Quiet Period, a publicly listed company cannot make any announcements about anything that could cause a normal investor to change their position on the company's stock. Normally, that means the company does not discuss any of the following:
New deals or wins signed in that current quarter. Announcements about previously sold implementations going live are allowed but must be explicitly described as such.
Management changes
Progress against company goals
Major product or service announcements
Major partnership announcements
So you see it is not me that is impatient as I am long and strong.
Maybe you can get all the information you need from IR.
Oh that's right that is where all of this started a few days ago. (We can't get any information from them on share count or nothing new from Dr. Missling)
Scam, Lack of transparency ?
I would like to refer you to paragraphs V.and VI of Anavex's Code of conduct as well as SEC's requirement for a possible "Quiet Period" posted previously on this board.
Dr. Missling reports to a Board of Directors that has a very great fiduciary responsibility. I don't feel that they would be involved in a scam and ruin their reputations.
V. FAIR DEALING
Directors, officers and employees are expected to deal ethically, fairly and honestly with all government officials as well as with the Corporation’s suppliers, customers, competitors and each other. Statements regarding the Corporation’s products and services must be true, and not be incomplete, misleading, deceptive or fraudulent. It is impermissible to take unfair advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts or any other such practice.
VI. CONFIDENTIALITY
Directors, officers and employees should maintain the confidentiality of information entrusted to them by the Corporation, except when disclosure is authorized under the Corporation’s Disclosure Policy or as otherwise legally mandated. Confidential information includes all non-public information that might be of use to competitors, or harmful to the Corporation, its suppliers or its customers, if disclosed. It also includes information that suppliers, customers and individuals or institutions involved in clinical trials or other product development activities have provided to the Corporation. Employees should take appropriate steps to limit distribution of such confidential information to only those employees of the Corporation who have a need to know such information in order to carry out their job responsibilities. It is the Policy of the Corporation that each of us must respect the proprietary information of other individuals or organizations with which the Corporation does business. Information obtained from public sources can legitimately be used in the Corporation’s business activities, but proprietary information obtained through improper means can never be used by any director, officer or employee in carrying out his /her job responsibilities.
Unless they are in a quiet period ! ??
Jon Jones I will re-post this as a possibility (and my hope).
Guidelines[edit]
During a Quiet Period, a publicly listed company cannot make any announcements about anything that could cause a normal investor to change their position on the company's stock. Normally, that means the company does not discuss any of the following:
New deals or wins signed in that current quarter. Announcements about previously sold implementations going live are allowed but must be explicitly described as such.
Management changes
Progress against company goals
Major product or service announcements
Major partnership announcements
I'm not sure that they can even state that they are in a quiet period if in fact they are. Xena would know that with her experience.
Could this be a possibility?
Quiet period
From Wikipedia, the free encyclopedia
In United States securities law, the quiet period (or waiting period) has "historically [meant], a quiet period of time extended from the time a company files a registration statement with the SEC until SEC staff declared the registration statement effective. During that period, the federal securities laws limited what information a company and related parties can release to the public."[1]
Under the rules of the Securities Act of 1933, as modified June 29, 2005, electronic communications, including electronic road shows and information located on or hyperlinked to an issuer's website are also governed. The rules changes of June 29, 2005, also included various changes which "liberalize permitted offering activity and communications to allow more information" for certain qualifying organizations.
In business finance, a waiting period (or quiet period) is the time in which a company making an IPO must be silent about it, so as not to inflate the value of the stock artificially. It is also called the cooling-off period.
Guidelines[edit]
During a Quiet Period, a publicly listed company cannot make any announcements about anything that could cause a normal investor to change their position on the company's stock. Normally, that means the company does not discuss any of the following:
New deals or wins signed in that current quarter. Announcements about previously sold implementations going live are allowed but must be explicitly described as such.
Management changes
Progress against company goals
Major product or service announcements
Major partnership announcements
I think a "Quiet Period" or "Waiting Period" might be a possible reason to gag the TA.
Expert opinion requested here. TIA
How about some conspiracy theory fun ?
1. Anavex reported great results at CTAD 2015
2. Stock was shorted, distorted, manipulated and law suits filed.
3. Congress requested to meet with Dr. Missling and he explained the problems Anavex is having to save the government money and to save
"Obama Care".
4.SEC meets with Anavex at the request of Congress.
5. Plan is developed to monitor and record all transactions, posts, articles and lawsuits filed on Anavex around the AAIC-2016 Conference in July and CTAD-2016 Conference in December as well as any other positive news release.
6. Then after the holidays SEC goes to work to be sure the "Most Hated Man in America" previously at Turing Pharmaceuticals will have the company of many of his associates in the future and for a long time!!
(I don't know how to get a smiley face here like Mac does)
LOL!! Boy I need to learn how to underline on these posts ! I'll try this Clinical Trials on Alzheimer's Disease.
When I wrote CTAD I was referring to the acronym for insert-text-herelinical insert-text-hererials on insert-text-herelzheimer's insert-text-hereisease. I am sorry if that was confusing.
Workshop session at CTAD
Makemdaze - I would like to get your thoughts on this session on Friday.
If I interpret this correctly it looks like Anavex's approach to trials might get discussed by Paul Aisen (member of our SAB).
WORKSHOP
New Trends in Clinical Trial Designs In Search of
Next Generation Treatments
Part I: Assessing a potential disease modifying
effect: Delayed Start Design and Analysis
Paul Aisen, MD
Alzheimer’s Therapeutic Research Institute, University of Southern California, San
Diego, CA, USA
One of the key interests in developing the next generation
AD treatments is demonstrating a potential disease modifying
effect. Delayed start design has been proposed as a viable
clinical trial design to assess whether an observed treatment
effect is due to symptomatic effect or disease modifying
effect. This approach was endorsed in the FDA draft guidance
for clinical development of AD drugs. This short course will
introduce the background of the Delayed Start design, provide
key considerations of design elements, and describe novel
statistical analysis methods and interpretation of results.
Examples from actual clinical trials in AD that have implemented
the design and analysis will be shared. There will be time for
Q&A and interactions with participants
Squeeze trigger price
I ran on to this this morning. It was an article in "4 Trader" posted on another site. I can't get a link to it and don't want to copy the entire article here. It is a service of Buyins.net.
BUYINS.NET: AVXL SqueezeTrigger Price is $3.36. There is $16,009,997 That Short Sellers Still Need To Cover.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/19/2016 | 10:03am EDT
The Wall Street Transcript
The interview was published October 21st.
The Wall Street Transcript The Wall Street Transcript - In-Depth Interviews for Investors
HOME
EXPERTS
REPORTS
PRODUCTS
NEWS
ABOUT US
CONTACT US
SEARCH
LOGIN
Series: Technology Healthcare Natural Resources Industry & Services Consumer Financial Services General Investing
Medical Research, Diagnostic Substances & Life Science Tools
October 21, 2016
Companies covered: BioTime, Inc. (AMEX:BTX), PhaseRx, Inc. (NASDAQ:PZRX), Dynatronics Corporation (NASDAQ:DYNT), Anavex Life Sciences Corp. (NASDAQ:AVXL), Cellectis S.A. (NASDAQ:CLLS), Digipath, Inc. (OTCMKTS:DIGP), EDAP TMS S.A. (NASDAQ:EDAP), BioSig Technologies Inc (OTCMKTS:BSGM), DelMar Pharmaceuticals Inc (NASDAQ:DMPI), Pressure BioSciences Inc. (OTCMKTS:PBIO), Clearside Biomedical Inc (NASDAQ:CLSD), Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Aimmune Therapeutics Inc (NASDAQ:AIMT), DBV Technologies S.A. (NASDAQ:DBVT), Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), Tobira Therapeutics Inc. (NASDAQ:TBRA), Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), United Therapeutics Corporation (NASDAQ:UTHR), Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), Allergan, Inc. (NYSE:AGN), Edwards Lifesciences Corporation (NYSE:EW), Medtronic, Inc. (NYSE:MDT), ABIOMED, Inc. (NASDAQ:ABMD), Wright Medical Group, Inc. (NASDAQ:WMGI), DexCom, Inc. (NASDAQ:DXCM), Insulet Corporation (NASDAQ:PODD), ResMed Inc. (NYSE:RMD)
Buy ($175)
Interview with the President and CEO: PhaseRx, Inc. (NASDAQ:PZRX)
Robert W. Overell
Interview with the Founder, Chairman and CEO: Cellectis S.A. (NASDAQ:CLLS)
Andre Choulika
Interview with the Co-CEO: BioTime, Inc. (NYSEMKT:BTX)
Adi Mohanty
Interview with the Founder, COO and President and the Chief Science Officer: Digipath, Inc. (OTCMKTS:DIGP)
Todd Denkin; Cindy Orser
Continued Innovation and Stability in the Medical Device Space
Raj Denhoy
Interview with the CEO: EDAP TMS S.A. (NASDAQ:EDAP)
Marc Oczachowski
Interview with the President and CEO: Anavex Life Sciences Corp. (NASDAQ:AVXL)
Christopher U. Missling
Interview with the Chairman, President and CEO: Dynatronics Corporation (NASDAQ:DYNT)
Kelvyn H. Cullimore
High Risk and High Growth Potential in Small-Cap Life Sciences Space
Jay Albany
Investing in Best-in-Class Emerging Pharmaceuticals
Liana Moussatos
Response to your post.
I am hoping that some knowledgeable people will weigh in on the question you posed neiu. I am wondering if Biogen might have the "Plus".
I don't think MJFF would publicize which companies they invited to submit and I would be sure that Anavex if invited would not publicize it either.
That would diminish the "ceremony" of the awards.
MJFF proposal dates.
Yes, I am hoping that AVXL was invited and made their proposal August 5th this year.
MJFF Conference
I have it on my calendar as Oct. 24th and I believe there will be an announcement.
About the Conference
Register Here
The Parkinson's Disease Therapeutics Conference is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development. The 10th Annual PD Therapeutics Conference will be held on October 24, 2016 at Convene Midtown East, New York City.
We are delighted to have Jesse Cedarbaum, MD chair our 2016 event.
The PD Therapeutics Conference brings together 300 research and business development professionals from both academia and industry and showcases the most exciting and innovative research from MJFF's research portfolio. Novel advances in basic and translational research from both academic and industry labs are highlighted through speaker presentations and a poster session. The event is a platform for field leaders to share new and unpublished results and for fostering new relationships and collaborations.
2016 program information below.
Amatuer17 - You might be interested in reading neiu's post #77241 that had a link to a brochure that was printed when Anavex was still located in Greece.
It has information on all that they were working on at that time. I found it rather informative.
I did not realize that they had an 11,000 sq. ft. lab at that time also.
Here is the link to the brochure.
https://www.google.ca/url?sa=t&source=web&rct=j&url=http://anavex.com/pdf/ANAVEX%2520Corporate%2520Brochure.pdf&ved=0ahUKEwjA84C6lsLPAhWFND4KHRkMDgYQFggbMAA&usg=AFQjCNGTWsT32HqCIIV9rMq0uPdhiLeQYg&sig2=WnGEh7BPqdOA6kHaVfkKdA
Missling knows something
Xena you made this statement in your post #76858
XenaLives Member Level Friday, 09/30/16 11:40:08 AM
Missling knows something (well a lot of somethings) that we don't know and he says later rather than sooner.
Here is something I copied after Missling met with congress earlier this year confirming your statement.
"We think differently and we have no fear" Dr. Missling's words spoken in Washington D.C when asked why can Anavex succeed where so many failed.
Xena - I don't recall that the company attended any of these type "higher powered" investors conferences last year like they are now. It seems to be a high priority at this time which is a good thing imo.
It is RETT Syndrome not R H E T T
I have read nearly every post for over a year and I am surprised that so many continue to refer to the disease incorrectly.
Rhett is either the first name of Rhett Butler in "Gone with the Wind" or the name of one of the comic duo "Rhett and Link". According to Wikipedia it is a boys name that is growing in popularity.
Anavex Life Sciences appears to building a platform of drugs that addresses some of life's most devastating diseases. Let us pray that they will be successful.
I really appreciate the posts of the knowledgeable people on this board. Please keep those of us without the scientific knowledge well informed with your interpretations of news. Thank you for your effort.